CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $254,213 | -23.9% | 5,620 | -31.6% | 0.14% | -29.4% |
| Q4 2022 | $334,074 | -60.3% | 8,218 | -36.2% | 0.19% | -62.6% |
| Q3 2022 | $842,000 | -69.2% | 12,878 | -71.4% | 0.52% | -68.4% |
| Q2 2022 | $2,737,000 | -45.6% | 45,036 | -43.8% | 1.64% | -32.6% |
| Q1 2022 | $5,027,000 | +29.7% | 80,082 | +27.9% | 2.44% | +18.6% |
| Q4 2021 | $3,876,000 | -42.8% | 62,609 | +3.5% | 2.06% | -28.8% |
| Q3 2021 | $6,772,000 | +4.9% | 60,499 | +51.7% | 2.89% | -8.3% |
| Q2 2021 | $6,458,000 | +39.9% | 39,891 | +5.3% | 3.15% | +26.2% |
| Q1 2021 | $4,617,000 | -29.1% | 37,892 | +13.2% | 2.50% | -26.4% |
| Q4 2020 | $6,509,000 | – | 33,480 | – | 3.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |